Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus

Recently a number of cases of drug induction or exacerbation of lupus erythematosus (LE) specific skin disease have been described in the literature. Many of the responsible medications are also known for their ability to induce a lichenoid tissue reaction. Aminoquinoline antimalarials are currently the first line of therapy in cutaneous LE specific skin disease. Lichenoid tissue reactions are among the most common cutaneous side effects of aminoquinolone antimalarials. We report three cases of aminoquinolone antimalarial induced or exacerbated LE specific skin disease. We also review the pathophysiology of LE specific skin disease and propose a mechanism by which induction of the lichenoid tissue reaction may result in Koebnerization of LE specific skin lesions.

[1]  M. David,et al.  [Subacute cutaneous lupus erythematosus induced by terbinafine]. , 2006, Harefuah.

[2]  E. Racila,et al.  Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus , 2003, Lupus.

[3]  A. Ormerod,et al.  Subacute cutaneous lupus erythematosus associated with phenytoin , 2002, Clinical and experimental dermatology.

[4]  J. Callen,et al.  Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. , 2002, Archives of dermatology.

[5]  B. Stricker,et al.  Etanercept-induced subacute cutaneous lupus erythematosus. , 2001, Rheumatology.

[6]  J. Callen,et al.  Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. , 2001, Archives of dermatology.

[7]  J. Gómez-Reino,et al.  Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis , 1999, The Journal of pathology.

[8]  C. Magro,et al.  Lichenoid and subacute cutaneous lupus erythematosus‐like dermatitis associated with antihistamine therapy , 1999, Journal of cutaneous pathology.

[9]  C. Magro,et al.  The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity , 1998, Journal of cutaneous pathology.

[10]  J. Ahearn,et al.  C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. , 1997, Journal of immunology.

[11]  A. Rosen,et al.  Ultraviolet light-induced keratinocyte apoptosis: A potential mechanism for the induction of skin lesions and autoantibody production in LE , 1997, Lupus.

[12]  D. Green,et al.  Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)- mediated T cell apoptosis , 1996, The Journal of experimental medicine.

[13]  A. Rosen,et al.  DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis , 1995, The Journal of experimental medicine.

[14]  C. Magro,et al.  Diltiazem and subacute cutaneous lupus erythematosus-like lesions. , 1995, The New England journal of medicine.

[15]  P. Herranz,et al.  Subacute cutaneous lupus erythematosus associated with cilazapril , 1995, The Lancet.

[16]  R. Stadler,et al.  Immunohistochemical analysis of chronic discoid and subacute cutaneous lupus erythematosus—relation to immunopathological mechanisms , 1995, The British journal of dermatology.

[17]  T. Provost.  The relationship between discoid and systemic lupus erythematosus. , 1994, Archives of dermatology.

[18]  A. Rosen,et al.  Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes , 1994, The Journal of experimental medicine.

[19]  S. Halevy,et al.  Lichenoid drug eruptions. , 1993, Journal of the American Academy of Dermatology.

[20]  S. Imamura,et al.  Oral Contraceptive‐induced Lupus Erythematosus in a Japanese Woman , 1991, The Journal of dermatology.

[21]  R. Sontheimer,et al.  Pathogenesis of anti-Ro/SS-A autoantibody-associated cutaneous lupus erythematosus. , 1990, Dermatologic clinics.

[22]  Y. Shiomi,et al.  Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin. , 1989, Journal of the American Academy of Dermatology.

[23]  D. Wallace.  The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. , 1989, Seminars in arthritis and rheumatism.

[24]  C. Neumann.  [Induction of subacute cutaneous lupus erythematosus by psoralen UV-A therapy]. , 1987, H+G Zeitschrift für Hautkrankeheiten.

[25]  D. Weedon.  The lichenoid tissue reaction , 1985, International journal of dermatology.

[26]  F. Bauer.  Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis) , 1981 .

[27]  H. Pinkus.  Lichenoid tissue reactions. A speculative review of the clinical spectrum of epidermal basal cell damage with special reference to erythema dyschromicum perstans. , 1973, Archives of dermatology.

[28]  J. Deng,et al.  Thiazide diuretics induce cutaneous lupus-like adverse reaction. , 1995, Journal of toxicology. Clinical toxicology.

[29]  J. Guilaine,et al.  [Subacute lupus erythematosus and methysergide]. , 1968, Bulletin de la Societe francaise de dermatologie et de syphiligraphie.